The conversation around semaglutide and employer benefits plans has been building for a few years now. In the spring of 2026, it moved from theory to reality. Canada became the first G7 country to approve a generic version of Ozempic, with two generics now authorized by Health Canada and roughly seven more submissions currently under review. Generic semaglutide is on pharmacy shelves, prices have already dropped significantly, and more competition is on the way.

For employers, this changes the conversation around semaglutide coverage in a pretty significant way. But the story doesn’t end there. The broader GLP-1 landscape is expanding quickly, and the implications for group benefits plans go well beyond a single drug’s price point.

Here’s what’s worth knowing right now.

What’s Changed With Generic Semaglutide

Health Canada authorized the first generic semaglutide in late April 2026, manufactured by Dr. Reddy’s Laboratories, followed shortly after by a second approval for Canadian-based Apotex. Both are pharmaceutically equivalent to brand-name Ozempic and have met Health Canada’s standards for safety, efficacy, and quality.

The pricing impact has been immediate. Brand-name Ozempic has already dropped in price by more than 50 percent in response to generic competition. Industry experts suggest costs could fall even further as more generics enter the market and manufacturers scale up production, with some estimates pointing to potential savings of up to 75 percent compared to original brand pricing.

A few things for employers to keep in mind:

• Generic semaglutide is currently indicated for type 2 diabetes management, not weight loss. The higher-dose Wegovy formulation used for obesity treatment remains patent-protected.

• Availability may be inconsistent in the near term as manufacturers work to meet demand. Provincial drug plan coverage is still being determined and will vary by province.

• Under Canada’s Pan-Canadian Pharmaceutical Alliance model, the first generic typically enters at 75 to 85 percent of the brand price, with further reductions as more competitors arrive.

If your plan covers semaglutide, now is a good time to look at your drug policies and preferred drug lists to make sure they reflect what’s available. A Quinn advisor can help you think through what adjustments make sense for your specific plan.

The Bigger Picture – GLP-1 Drugs Are Just Getting Started

The arrival of generic semaglutide is good news for cost management, but employers need to understand that overall GLP-1 spending is unlikely to decline in the years ahead. The reason is straightforward: these drugs are being approved for an expanding range of conditions, and a new wave of GLP-1 therapies is moving through the pipeline.

Health Canada has already approved Wegovy for use beyond weight loss, including for cardiovascular risk reduction and metabolic dysfunction-associated steatohepatitis (MASH), a liver condition affecting an estimated five to six percent of Canadians. Future expanded indications under consideration include obstructive sleep apnea and other cardiometabolic conditions.

At the same time, a new generation of GLP-1 treatments is in development. These next-generation therapies are expected to be more effective, last longer between doses, and increasingly become available in oral form. While most are not yet before Health Canada, late-stage clinical trials signal that they are coming, and they will add new coverage decisions to the conversation.

What this means for employers:

• GLP-1 drugs are shifting from niche medications to a broad chronic disease management category

• Plan sponsors who haven’t yet defined their philosophy around GLP-1 coverage will increasingly need to do so

• The question is no longer just whether to cover these drugs, but how, for which conditions, and with what guardrails

If your plan covers semaglutide, now is a good time to look at your drug policies and preferred drug lists to make sure they reflect what’s available. A Quinn advisor can help you think through what adjustments make sense for your specific plan.

What Employers Should Be Doing Now

The generic arrival creates a natural opening to revisit your current approach to GLP-1 coverage and drug plan management more broadly. A few practical steps worth considering:

1. Review your current drug formulary and policies to understand what’s covered, under what conditions, and whether your existing rules are still fit for purpose given the changing landscape.
2. Talk to your advisor about preferred drug list updates and whether generic substitution language is in place.
3. Think through employee communication: employees may have questions about being switched from brand-name to generic, and clear messaging will go a long way.
4. Consider the broader cost trajectory: even with generics reducing semaglutide costs, the pipeline of new GLP-1 therapies means this is a category that will keep growing.

Generic semaglutide is good news for drug plan costs, but the full picture is more complicated than the price drop suggests. The GLP-1 landscape is expanding, new therapies are on the horizon, and the decisions employers make now around coverage and plan design will shape their costs for years to come.

If you’d like to understand how these changes could affect your specific plan, we’re happy to help.